Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2025 and updated full-year guidance.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025.

Group sales grew by 7% at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and diagnostics.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2025.

Danaher reported a 5 percent year-over-year increase in third quarter revenues on Tuesday that was partially due to higher-than-anticipated revenues from Cepheid's respiratory testing business.

In preliminary results reported on Wednesday after the close of the market, Becton Dickinson said its revenues in the fiscal fourth quarter of 2025 increased 8 percent year over year. The firm also announced the upcoming departure of its CFO and disclosed a transition plan for the position.

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2025.

International business has become a key performance driver. Mindray generated RMB 8.33 billion in overseas revenue, accounting for 49.77% of its total, up 5.39% year-on-year. Assure Tech and Alltest reported over 90% of revenue from abroad, while Cowin Biotech grew overseas revenue 40.83%.

Profitability among IVD companies diverged sharply. Mindray led with a net profit of RMB 5.069 billion in H1 2025, followed by Andon Health (RMB 920 million) and Snibe (RMB 771 million).